{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '9.', 'STATISTICAL CONSIDERATIONS', '9.1.', 'Overview', 'The objective of this study is to evaluate the health-related quality of life, efficacy, and safety of', 'apremilast compared to placebo, for 16 weeks, and evaluate the long-term effects of apremilast', 'on quality of life, efficacy, and safety for up to 52 weeks in subjects with manifestations of', 'plaque psoriasis and impaired quality of life.', '9.2.', 'Study Population Definitions', 'Four analysis populations will be defined for this study. These populations include the safety', 'population, the intent to treat (ITT) population, the per protocol (PP) population, and the', 'apremilast exposure population.', 'The Safety population will consist of all subjects who are randomized and receive at', 'least one dose of investigational product (IP). This set of subjects will be included in', 'the treatment group corresponding to the IP they actually receive. This will be the', 'population for all safety analyses on data from the Placebo-controlled Phase.', 'The ITT population will consist of all subjects who are randomized. This will be the', 'primary population for the primary endpoint and all other quality of life and efficacy', 'analyses. Baseline summaries will also be based on the ITT population.', 'The PP population will consist of all subjects who are in the ITT population,', 'complete the Placebo-controlled Phase, and have no major protocol violations. The', 'PP population will only be used to supplement the primary endpoint ITT analysis.', 'The apremilast (APR) exposure population will consist of only those subjects who', 'receive at least one dose of apremilast treatment. The APR exposure population will', 'only be used for the purposes of safety reporting including all safety data during', 'apremilast treatment.', '9.3.', 'Sample Size and Power Considerations', 'Using an exploratory analysis on a subset of subjects meeting the following criteria: 1) ScPGA >', '3 at baseline or 2) NAPSI > 1 at baseline or PPPGA > 3 at baseline and DLQI > 10 at baseline in', 'the PSOR-008 and PSOR-009 Phase 3 studies, it was estimated that the proportion of subjects', 'who achieved a > 4-point reduction from baseline in DLQI was 0.50 (97 responders out of 193', 'subjects) and 0.83 (337 responders out of 406 subjects) for placebo and apremilast 30 mg,', 'respectively.', 'Assuming a placebo DLQI Responder proportion of 0.50 at Week 16, a minimum total sample', 'size of 210 subjects (140 allocated to apremilast 30 mg and 70 allocated to placebo) is needed to', 'detect a 0.20 difference in the DLQI Responder proportions between apremilast and placebo with', 'at least 0.807 power using a two-sided test at the 0.05 level of significance. This sample size', 'calculation is based on an unpooled variance, and was determined using the commercial software', 'EaST, Version 6.3. Allowing for a 18% discontinuation rate prior to Week 16, the sample size', 'was revised from a total of 210 subjects to a final sample size of 255. If there are no', 'discontinuations prior to Week 16, then the power with a sample size of 255 subjects would', 'Confidential and Proprietary', '46', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'increase to 0.872. Hence when addressing missing data due to discontinuations with multiple', 'imputations, we would expect the power to be in between the bounds of 0.807 (based on 210', 'subjects) and 0.872 (based on 255 subjects), as the analysis that incorporates multiple imputation', 'under a missing at random assumption will always be more efficient compared to the observed', 'analysis when the missing data is actually missing completely at random.', '9.4.', 'Background and Demographic Characteristics', \"Subjects' age, height, weight, and baseline characteristics will be summarized using descriptive\", 'statistics, while sex, race, and other categorical variables will be provided using frequency', 'tabulations. The disease characteristics at baseline will also be summarized using appropriate', 'descriptive statistics. These descriptive statistics will be summarized by the randomized', 'treatment group using the ITT population.', '9.5.', 'Subject Disposition', 'The distribution of enrollment by site will be provided. Subject disposition (analysis population', 'allocation, entered, completed, discontinued, along with primary reason for discontinuation) will', 'be summarized using frequency and percent for the Placebo-controlled Phase (Weeks 0 to 16)', 'and the apremilast Extension Phase (Weeks 16 to 52). Protocol deviations will be summarized', 'using frequency tabulations.', '9.6.', 'Efficacy Analysis', 'Statistical comparisons will be made between apremilast and placebo at Week 16. The statistical', 'test on the primary endpoint will be at a 2-sided 0.05 significance level with treatment effect', 'estimates and the corresponding 95% confidence intervals (CIs) being reported. Any p-values', 'reported other than for the primary endpoint analysis will be considered as summary statistics.', 'Descriptive statistic summaries for the observed data will also be provided by visit and', 'randomized treatment group.', '9.6.1.', 'Primary Endpoint', 'The primary endpoint is the proportion of subjects achieving a > 4 point reduction from baseline', 'in DLQI at Week 16. It will be analyzed using the ITT population. However, a supplemental', 'analysis will be performed using the PP population.', 'The primary analysis for the primary endpoint at Week 16 will be the Cochran-Mantel-Haenszel', '(CMH) test adjusted for the stratification factor at randomization (ie, the 5 difficult to treat', 'manifestation types). This form of the CMH test will use the sample sizes in each of the strata as', 'weights when estimating the adjusted difference in the treatment proportions, constructing 95%', 'Wald confidence intervals for the difference, and conducting a statistical test of no difference', 'between the treatment proportions (ie, Ho: TAPR - TPBO = 0 as the null hypothesis).', 'All reasonable attempts will be made to prevent missing data from occurring in this study,', 'especially through Week 16. However, in the case of missing data at Week 16 a multiple', 'imputation (MI) method will be incorporated into the primary analysis. Imputations will be made', 'on the continuous-like scale of the total DLQI score, and then dichotomized according to the', 'primary endpoint definition prior to performing the CMH analysis. The aim of the multiple', 'Confidential and Proprietary', '47', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}